Top Stories News

Rexahn Pharmaceuticals has completed enrollment for a Phase II clinical trial of its experimental cancer drug Archexin.

Evotec has agreed to acquire the remaining 30% of its Joint Venture with DIL Ltd., India for $2.3 million.

Japanese drugmaker Santen Pharmaceutical said on Wednesday it has agreed to buy 50.55 percent of French biopharma Novagali.

Helsinn Healthcare and Riemser Arzneimittel signed an agreement to grant marketing rights in Germany to Riemser for a next-generation treatment in development for the prevention of chemotherapy-induced nausea and vomiting.

The collaboration aims to develop new, robust and reproducible biochemical assays for the analysis of the biological activity of therapeutic monoclonal antibodies.

Pharmaceutical wholesaler AmerisourceBergen has agreed to buy TheraCom, a subsidiary of CVS Caremark, for $250 million.

Finnish biotech Biotie Therapies will purchase Italian biopharmaceutical firm Newron Pharmaceuticals for €45m.

Lonza has entered into a strategic alliance with Australia-based Mesoblast for the production of Mesoblast's adult stem cell therapies.

PCCA President urges member pharmacists to continue their efforts to reduce the growing issue of drug shortages.

Six drugs are currently in development at the facility, including Merck's candidate drug for the treatment of hepatitis C and a dual high cholesterol/type II diabetes medication.

The South Korean biotech forms a partnership with Mayo Clinic to focus on research into chemical compounds that target a type of protein known as TDP-43.

Loxbridge Research signed a joint venture agreement to form Altermune Technologies to develop new therapeutics targeting combat resistant pathogens.

New York-based Bristol-Myers Squibb has inked an agreement with Ambrx to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein and the Relaxin hormone.

This will be the second auditing and inspection of manufacturing facilities in China. The CDSCO delegation inspected five manufacturing sites in China in May which have been found to be in good condition.

The partnership will initially focus on diabetes - a core business area in which Lilly has deep expertise.

Ono Pharmaceutical, based in Osaka, has granted BMS exclusive rights to develop and sell the potential cancer treatment worldwide except in Japan, Korea and Taiwan.

Sanofi Pasteur has announced a research and development collaboration with the University of California on an immunological approach to acne prevention and treatment.

The 12 New Drug Advisory Committees will advise the Drugs Controller General of India in matters for review of applications of new drugs and clinical trials.

To date, a total 11 medicines for use in patients with Alzheimer's disease have been authorised in the EU on the recommendation of the EMA.

Some state-funded hospitals in Italy and Portugal are also failing to pay their bills, and Roche has warned that drug deliveries may also be halted in Spain for the same reason.

Teva will initially invest $7.5 million in CDI for the development of an antiviral drug targeting the polymerase enzyme of the hepatitis C virus.

Chesapeake Pharmaceutical and Healthcare Packaging has agreed to buy Cortegra Group, a US-based contract producer of packaging and leaflets.

GSK has formed a five-year partnership with Formula 1 team McLaren to drive its manufacturing operations and research.

The programme, known as Changing Diabetes in Children, aims to reach over 2500 kids with type I diabetes from underprivileged families over the next two years.

Biotechnology firm Genentech has submitted a NDA for vismodegib to the FDA for the treatment of advanced basal cell carcinoma.

Frontage will provide bioanalytical method development and sample processing, formulation development and clinical trial product supplies for Spaulding.

The two companies have signed an exclusive licence agreement for the development and commercialization of a tumours treatment currently in Phase I development.

The joint venture, named Aurospharma, will include a manufacturing facility near Moscow, due to be completed in 2013.

Under the agreement, Ark will provide manufacturing and related services to support the development of PsiOxus’ ColoAd1 programme for the treatment of colorectal cancer.

Sucampo Pharmaceuticals signs an R&D collaboration deal with Numab for the discovery of antibodies using the latter's high-affinity antibody technology.

Cuban medical authorities have launched the distribution of CimaVax-EGF, the world's first lung cancer vaccine, in Cuban hospitals free of charge.

This study will examine the effectiveness of HA-Irinotecan, which utilizes Alchemia's technology to target the anti-cancer drug irinotecan to the tumor.

Researchers has identified a gene responsible for chronic back pain.

Esbriet will be commercially available in Europe for the first time since it was approved by the European Commission in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis.

Bristol-Myers Squibb has completed its previously announced acquisition of small-molecule pharmaceutical company Amira Pharmaceuticals.

GlaxoSmithKline will receive $94m from the US Department of Health and Human Services for a promising new antibiotic research and testing.

The new programme will provide a boost to bringing research results rapidly to market, according to Germany Trade & Invest.

BioLineRx announced yesterday its worldwide, exclusive license agreement with Ramot at Tel Aviv University for a neuropathic and inflammatory pain treatment.

Austria's F-Starfor announced yesterday the agreement with Merck Serono for the discovery of new antibody-derived therapeutics against inflammatory disease targets.

Evotec and Roche have teamed up to develop and commercialize MAO-B inhibitor of Evotec for the patients with Alzheimer's disease.

The WHO and the FIP signed a joint statement seeking to involve pharmacists in tuberculosis care and control.

Merck originally licensed the rights to the programme in 2007 in a deal potentially worth as much as $170.5m.

Pfizer has granted Sanofi a licence to manufacture a generic version of the product and launch it after Lipitor's patent expires in the country on 7 May 2012.

Oxford Pharmascience partners with University of London to have the option to license and research an advanced colonic drug delivery technology.

According to trial results announced recently, Crestor, the statin drug from AstraZeneca, failed to best Lipitor at clearing clogged arteries.

The new research site will be Pfizer’s Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units.

Pfizer, the world’s largest drugmaker, settles a lawsuit with the Indian generic-drug maker Dr. Reddy’s Laboratories over the cholesterol treatment Lipitor.

Teva has signed an agreement with Sinclair IS to gain exclusive commercialisation rights of oncology medication Episil in Germany, Spain, Poland, Switzerland and the Czech Republic.

Bayer HealthCare's affiliate, MEDRAD, Inc. acquires Pathway Medical Technologies to strengthen its MEDRAD Interventional business by expanding its presence in the field of vascular intervention technologies.

Biopharmaceutical firm OXiGENE, Inc. decides to restructure in an to focus resources on its most promising early-stage clinical programs.

Pfizer's subsidiary, Eclipse Acquisition Corp. , has extended the expiration date of its tender offer for Icagen.

Under the agreement, ICON will become a preferred provider for full-service clinical pharmacology and exploratory clinical studies.

Valeant Pharmaceuticals will acquire cold and flu medicine maker Afexa Life Sciences for approximately $76 million.

The study of 549 hospitals indicates that 52% of respondents purchased one or more pharmaceutical products from back-door suppliers during the past two years.

Adimab will receive upfront payments and preclinical milestones from both companies, and is eligible to receive clinical development milestones and royalties on sales.

Under terms of the deal, Zymeworks will receive an up-front fee and could earn research, development, and regulatory milestones of up to $187 million.

India's Piramal plans to invest at least $1.5 billion in biotech acquisitions and Big Pharma joint ventures to expand its overseas business.

Eisai will establish its Canadian headquarters in Mississauga, Ontario and the expansion into Ontario will increase access to a variety of therapies and medications.

British health authorities warned that packages of an over-the-counter painkiller were found to contain antipsychotic drugs.

Two UK firms have agreed to collaborate on drug discovery.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Ms. Yu Lingmin, Manager of NO.1 Pharmaceutical Dept, A.H.A Internatio...

Sanofi announced to acquire India's nutraceuticals company Universal Medicare. The transaction is expected to close in the fourth quarter of this year.

The combination of two research organisations will enable them to offer integrated pharmaceutical and clinical development solutions.

The HHS has announced the award of $137 million of grants to states to fund prevention and health improvement services and programs.

Indian Clinigene International Ltd. and U.S. Spaulding Clinical Research will cooperate to develop their clinical pharmacology services.

Catalent Pharma Solutions announced that it will buy the clinical trial supplies business of Aptuit LLC for $410 million.

The two companies will reconfigure their assets and personnel to maximize design and engineering operations and build out their manufacturing facilities.

The certificate states that WuXi's BAS facility in Shanghai is able to carry out ADME, toxicokinetic and pharmacokinetic studies, and hERG assay and biomarker studies with respect to OECD and EU GLP principles.

The collaboration will combine Bend’s formulation/processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development expertise.

Par Pharmaceutical Companies said it has agreed to acquire privately-held Anchen Pharmaceuticals for $410 million in cash.

The study found that of 192 pharmaceutical adverts, only 18% were compliant with the US FDA guidelines.

With the new premises, Novo Nordisk will be consolidating a number of administrative functions currently scattered across Greater Copenhagen.

A study estimates that needle-free drug delivery methods will have annual revenue growth of 15.1% on average from 2011 to 2016 to reach US$6.2bn.

Takeda will have a JPY23.9bn (US$312m) government subsidy to develop a new influenza vaccine.

The two pharma firms have added the development and commercialization of additional strengths of generic Focalin XR for the U.S. market to their existing agreement.

Boehringer Ingelheim will apply ProBioGen's technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.

Paladin Labs will purchase drug technology developer Labopharm in a deal valued at over $20.4 million.

Roche's Toclizumab is already licensed to treat adults with severe arthritis, but as of today the drug will be available for children.

According to the survey, changes in healthcare legislation and reform top the list of business concerns of healthcare companies in the US and Asia.

Carlyle Group is in exclusive talks to buy North Carolina-based CRO company Pharmaceutical Product Development.

Swiss firm 4-Antibody inked a collaboration agreement with Human Genome Sciences for the discovery and development of fully human antibodies.

The acquisition expands GE Healthcare’s offering of products and services for cell biology research and the discovery and manufacture of biopharmaceuticals.

The company has paid $175,000 to four families in the first of a series of payments as part of an out-of-court settlement reached in 2009.

Bayer HealthCare will support WHO and the Stop TB Partnership in the fight against multidrug-resistant tuberculosis by making 620,000 tablets of the antibiotic moxifloxacin available to WHO.

Pfizer has partnered with the University of California's San Diego Health Sciences in a drug discovery collaboration.

According to a new report focused on M&A activity, 18 biotech companies were sold during the first half of this year for total upfront values of $51.6 billion.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Mr. Zhou Jianmin, Board Member /Deputy General Manager of Liaocheng W...

The approval follows the results from two Phase III trials assessing the safety and efficacy of BDP Nasal HFA in the treatment of SAR and PAR.

The project will focus on developing treatments across three technological platforms.

GNS will use clinical and molecular information from a Bristol-Myers Squibb clinical trial to build computer models to identify key molecular mechanisms.

The acquisition covers K-V Pharma's certain packaging, manufacturing and laboratory facilities, as well as equipment specific to the generic business.

Ipca said its UK subsidiary has acquired Onyx Research Chemicals, the holding company of Onyx Scientific Ltd, a contract manufacturing organisation.

Unigene will receive up to approximately $2.2 million in milestone payments from GSK to undertake certain development and manufacturing activities.

The UK's healthcare regulators have recommended against the prescription of Novartis' multiple sclerosis drug Gilenya to NHS patients due to uncertainties over its clinical effectiveness.

From a public health perspective, an ideal influenza vaccine would protect against multiple strains of the virus, regardless of their hemagglutinin structure.

The partnership will leverage the strengths of both companies and facilitate collaboration on integrated clinical services to engage pharmaceutical clients who demand a global footprint.

Under the agreement, MolMed will develop a production process for an investigational gene therapy for ADA-SCID, a very rare disease that affects approximately 350 children worldwide.

The number of drug approvals is set to increase further, with more than a dozen drug candidates still scheduled for review before the end of the year.

Pfizer hopes to sell an over-the-counter version of its best-selling drug Lipitor when its generic forms are available in November.

Vectura Group has inked a new US partnership deal for its generic lung drug VR315.

Under the terms of the agreement, Merck will receive specific rights to market PCV in certain designated territories and Serum will receive specific rights in other territories.

Celgene and Acceleron will jointly develop, manufacture and commercialize ACE-536, a novel protein therapeutic for the treatment of anemia.

Swiss drugmaker Novartis racked up 17 new drug approvals from 2000 to 2010. But over the past 60 years, the company has accounted for only 16.

Capsugel will maintain a corporate presence in the US. All Pfizer employees currently dedicated to this business will be transferred to Capsugel.

The pilot programs are part of the FDA's global strategy to ensure the safety and quality of imported products.

The New York-based pharma company has reported its second quarter financial results.

Merck is planning global submissions for ridaforolimus in Europe, the U.S., Canada, Asia-Pacific and Latin America and other key markets.

A new study says more than half the people who take opioids for chronic pain are likely to still be taking the painkillers five years later.

As part of the next phase of its restructuring programme, Merck expects to reduce its workforce by an additional 12 to 13% by the end of 2015.

The settlement will ensure that none of the 27 members of the economic and trading bloc will detain 'Made in India' consignments of generic medicines, which are transiting through EU ports.

Total first half sales in North America were EUR 4,393 million, an increase of 5.1 percent compared with first-half 2010 sales.

Russia's $1.3 billion federal program for the development of the pharmaceutical industry will help to persuade companies to buy APIs in Russia instead of India or China.

According to the World Health Organization, the world's seasonal flu vaccine production capacity will double by 2015.

Under the partnership, INC Research agrees to work with Debiopharm on future clinical studies.

GlaxoSmithKline reports its financial results for the second quarter ended June 30, 2011.

The CPHI, ICSE & BioPh China 2011 and P-MEC China 2011 were held in Shanghai from June 21, 2011 to June 23, 2011. During the exhibition, “CPHI-Online” had an interview with Mr. Chen Yuming, General Manager of Chengdu GELAIPU SCI & TECH, CO., ...

The EMA has agreed to a recall of Vimpat 15 mg/ml syrup because of a quality defect in some batches.

Lonza is in partnership with Genesis Biopharma to develop Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

At the time of the Hong Kong recall, GSK and health officials there emphasized that the amounts of plasticizer found weren't likely to cause harm to humans if they were taken at the proper doses.

Roche will deliver diagnostics to support the largest infant testing initiative in the world that aims to identify HIV-infected children during the first months of life.